News

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will present data from its aglatimagene besadenovec program in non-small cell lung cancer (NSCLC) in patients with progressive NSCLC despite immune checkpoint inhibitor (ICI) treatment, as well as clinical

Yahoo·09:00CADL▲+5.9%

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on September 30, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to 4 new employees, stock options to purchase an aggregate of 85,900 shares of the Company’s common stock, with a pe

Yahoo·16:05CADL▲+5.9%

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI

Peer-reviewed publication in Journal for ImmunoTherapy of Cancer reports median overall survival of 24.5 months in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to immune checkpoint inhibitors (ICI) NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today a

Candel Publishes Final Phase Of 2a Clinical Trial Results Of of Aglatimagene Besadenovec Plus Valacyclovir In Patients With Stage III/IV NSCLC Showing Inadequate Response To ICI.

Peer-reviewed publication in Journal for ImmunoTherapy of Cancer reports median overall survival of 24.5 months in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to immune checkpoint

Benzinga·04:11CADL▲+5.9%

CADL Slips Despite Encouraging Prostate Cancer Drug Data — Retail Believes Stock Is ‘Clearly A Buy And Hold’

Candel’s experimental therapy combined with radiation therapy improved outcomes in patients with localized prostate cancer

Yahoo·11:00CADL▲+5.9%

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

Novel systemic immune data demonstrated T-cell activation following local administration of aglatimagene. Together with recently disclosed evidence of persistent local immune remodeling, these findings provide mechanistic support for the long-term clinical outcomes, including disease-free survival and prolonged time to biochemical failure, time to metastasis, and time to salvage anti-cancer therapy, observed in this patient populationBiodistribution and shedding data from the PrTK05 phase 2 tria

Yahoo·08:30

Candel Therapeutics Announces Immunological Biomarker Data From Ongoing Phase 2 Prtk05 Trial In Patients With Intermediate-Risk Localized Prostate Cancer

Novel systemic immune data demonstrated T-cell activation following local administration of aglatimagene. Together with recently disclosed evidence of persistent local immune remodeling, these findings provide

Benzinga·04:33CADL▲+5.9%

Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4

Candel Therapeutics is upgraded to Strong Buy after phase 3 prostate cancer win; 30% lower recurrence supports 2026 BLA. Click for this CADL update.

SeekingAlpha·10:50CADL▲+5.9%

B of A Securities Upgrades Candel Therapeutics to Buy, Raises Price Target to $18

B of A Securities analyst Alec Stranahan upgrades Candel Therapeutics (NASDAQ:CADL) from Neutral to Buy and raises the price target from $12 to $18.

Benzinga·02:48CADL▲+5.9%

The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux

Prostate cancer awareness spotlights Pfizer's Xtandi, Novartis' Pluvicto and clinical-stage programs from Candel and Janux.

Yahoo·05:47CADL▲+5.9%

4 Prostate Cancer Drug Stocks to Watch During Awareness Month

Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.

Yahoo·10:12CADL▲+5.9%

Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors

Regulatory and quality expertise strengthens Board as Candel advances toward planned Biologics License Application (BLA) submission and potential commercial readiness NEEDHAM, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Martine Zimmermann, PharmD, to the

Yahoo·08:05CADL▲+5.9%

Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks Pricey

Candel Therapeutics (CADL) drew attention after reporting second quarter 2026 results that showed a net loss of US$38.91 million, compared with US$4.8 million a year earlier, indicating increased operating pressures. See our latest analysis for Candel Therapeutics. The latest earnings release landed alongside sharp share price gains for Candel Therapeutics, with a 1-day share price return of 12.03% and a 90-day share price return of 70.24%. The 3-year total shareholder return is also very...

Yahoo·12:14CADL▲+5.9%

Non-Metastatic Prostate Cancer Market to Exhibit Growth at a CAGR of 4% During the Forecast Period (2026-2036), as Pharmaceutical Companies Intensify Development of Advanced Therapies | DelveInsight

Recently published Non-Metastatic Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, non-metastatic prostate cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Yahoo·10:33

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

SeekingAlpha·18:54

B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12

B of A Securities analyst Alec Stranahan maintains Candel Therapeutics (NASDAQ:CADL) with a Neutral and raises the price target from $9 to $12.

Benzinga·10:23CADL▲+5.9%

CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4

If the FDA approves aglatimagene besadenovec in the treatment of certain patients with prostate cancer, it would mark the company’s first commercial product.

Yahoo·15:27CADL▲+5.9%

HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Candel Therapeutics (NASDAQ:CADL) with a Buy and maintains $23 price target.

Benzinga·08:06CADL▲+5.9%

Candel Therapeutics Q2 EPS $(0.52) Misses $(0.23) Estimate

Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.23) by 126.09 percent. This is a 477.78 percent decrease over losses of $(0.09) per

Benzinga·04:47CADL▲+5.9%